Insights Blog

Liquid Biopsy (LBx) continued to develop through February, featuring new clinical and research collaborations, many study results and trial launches, and M&A updates.

Read about the latest updates in the Next-Generation Therapeutics space in the month of February.

UK biotech M&A reveals Big Pharma’s shift from risky early-stage bets to premium-priced, revenue-ready acquisitions as the patent cliff looms.

A pragmatic, post-JPM and post-ATW look at the state of cell therapy development, from LVV design to CMC realities and scientific decision-making.

As focus shifts from lifespan to health span, a real question emerges: will value remain fragmented across well-capitalized point solutions, or concentrate in a handful of platforms that specialize in personalizing medicine across women’s life stages?

A Q&A with Matt Marlowe on China’s evolving sequencing landscape — and what it means for Illumina.